OTCMKTS:DCTHD Delcath Systems (DCTHD) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free DCTHD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.20▼$5.4550-Day Range N/A52-Week Range$1.22▼$63,000.00Volume172,774 shsAverage Volume771 shsMarket Capitalization$208,400.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Delcath Systems alerts: Email Address Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. About Delcath Systems Stock (OTCMKTS:DCTHD)Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.Read More Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. DCTHD Stock News HeadlinesMarch 21, 2024 | gurufocus.comDirector Gil Aharon Acquires 26,882 Shares of Delcath Systems Inc (DCTH)December 30, 2023 | benzinga.comDelcath Systems Stock (NASDAQ:DCTH) Insider TradesApril 30, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. December 30, 2023 | benzinga.comDelcath Systems Stock (NASDAQ:DCTH) Dividends: History, Yield and DatesAugust 31, 2023 | thestreet.comDelcath Liver Tumor Data ImproveAugust 15, 2023 | msn.comDelcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver TherapyAugust 11, 2023 | msn.comDelcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFAAugust 9, 2023 | msn.comDelcath Systems GAAP EPS of -$0.58 beats by $0.02, revenue of $0.5M misses by $0.24MApril 30, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. July 9, 2023 | thestreet.comDelcath Readies Pivotal Trial ResultsJune 19, 2023 | forbes.comBest iPad POS Systems Of 2023May 24, 2023 | msn.comHC Wainwright & Co. Reiterates Delcath Systems (DCTH) Buy RecommendationMay 15, 2023 | bbc.co.ukWhat is the digestive system?May 12, 2023 | thestreet.comDelcath: Safety Questions Behind FDA DelayMarch 27, 2023 | finance.yahoo.comDelcath Systems Announces up to $85 Million FinancingMarch 27, 2023 | markets.businessinsider.comDelcath Systems Inc. Q4 Loss increases, misses estimatesMarch 27, 2023 | finance.yahoo.comDelcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 27, 2023 | markets.businessinsider.comDelcath Announces FDA's Acceptance Of NDA Resubmission Of Hepzato KitFebruary 16, 2023 | markets.businessinsider.comDelcath Systems Announces Resubmission Of NDA For Hepzato KitDecember 15, 2022 | gurufocus.comAn Insider Just Bought Shares of Delcath Systems Inc; Could This Stock Be a Value Opportunity?November 8, 2022 | seekingalpha.comDelcath Systems slips despite Q3 beatSeptember 10, 2022 | seekingalpha.comDCTH Delcath Systems, Inc.August 10, 2022 | markets.businessinsider.comDelcath Systems Inc. Q2 Loss increases, misses estimatesJuly 27, 2022 | markets.businessinsider.comDelcath Systems to Host Second Quarter 2022 ResultsMarch 15, 2022 | benzinga.comDelcath Systems to Host Fourth Quarter and Full Year 2021 ResultsFebruary 4, 2022 | benzinga.comDelcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To LiverDecember 2, 2021 | benzinga.comDelcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data AnalysisSee More Headlines Receive DCTHD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2016Today4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:DCTHD Previous SymbolNASDAQ:DCTH CUSIPN/A CIKN/A Webwww.delcath.com Phone212-489-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,220,000.00 Net Margins-1,546.38% Pretax MarginN/A Return on EquityN/A Return on Assets-343.56% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.50 Sales & Book Value Annual Sales$3.41 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book Value($1,036.00) per share Price / Book-0.01Miscellaneous Outstanding Shares40,000Free FloatN/AMarket Cap$208,400.00 OptionableNot Optionable Beta-0.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesRoger G. Stoll Ph.D. (Age 74)Chairman of the Board Jennifer K. Simpson Ph.D. (Age 48)President, Chief Executive Officer, Director Barbra C. Keck (Age 39)Chief Financial Officer, Secretary John Purpura (Age 55)Executive Vice President - Global Head of Operations Simon C. Pedder Ph.D. (Age 56)Director William Dodge Rueckert (Age 64)Independent Director Marco Taglietti M.D. (Age 57)Independent Director More ExecutivesKey CompetitorsVerisante TechnologyOTCMKTS:VRSEFTodos MedicalOTCMKTS:TOMDFPresbiaOTCMKTS:LENSFQuantRx BiomedicalOTCMKTS:QTXBH-CYTEOTCMKTS:HCYTDView All Competitors DCTHD Stock Analysis - Frequently Asked Questions How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (OTCMKTS:DCTHD) announced its earnings results on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, topping analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same quarter in the prior year, the company posted ($686.00) earnings per share. When did Delcath Systems' stock split? Delcath Systems shares reverse split on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. This page (OTCMKTS:DCTHD) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
